Skip to content

The use of Bioactive Glass S53P4 as bone graft substitute in the treatment of chronic osteomyelitis and infected non-unions - a retrospective study of 50 patients.

The use of Bioactive Glass S53P4 as bone graft substitute in the treatment of chronic osteomyelitis and infected non-unions - a retrospective study of 50 patients. - bioactive glass in chronic osteomyelitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00011679
Enrollment
50
Registered
2017-05-24
Start date
2017-05-05
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M86

Interventions

Group 1: chronic osteomyelitis and/ or infected non-unions
retrospective analysis of all patients with COM and/ or infected non-unions, who obtained BAG-S53P4 after surgical debridement to fill their bone defects. Follow-up data will be performed during consu

Sponsors

BG Klinikum Duisburg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were the existence of COM and/ or infected non-unions (evidence of positive bacteriology and/ or positive histology of intraoperative removed samples). Period of treatment/ data analysis: 07/13 - 12/16

Exclusion criteria

Exclusion criteria: Exclusion criteria were aseptic non-unions and unavailable follow-up.

Design outcomes

Primary

MeasureTime frame
Primary endpoint is the successful control of infection during the follow-up period. Clinical control of signs of reinfection during consultation hours, as a rule after 6 weeks, 3, 6, 12 and 18 months. No reexacerbation: no signs of infection (redness, fistula etc) and no reoperations

Secondary

MeasureTime frame
Secondary endpoints were the absence of local or systemic reactions due to the implanted BAG (e.g. foreign body reactions, redness, swelling, increased secretion or allergic reactions), the time period to full weight bearing as well as the time period to radiologic detectable incorporation of BAG.

Countries

Germany

Contacts

Public ContactEva Steinhausen

BG Klinikum Duisburg

eva_steinhausen@yahoo.de0203 7688 3750

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 24, 2026